Completed PHASE2 INTERVENTIONAL 2-arm NCT01268527

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Sponsor: Eisai Limited

Interventions 0.005% E6201 0.01% E6201 0.03% E6201 0.05% E6201 0.1% E6201 0.2% E6201 Calcipotriene Placebo - 0.01% gel vehicle Placebo - 0.03% gel vehicle Placebo - 0.05% gel vehicle Placebo - 0.1% gel vehicle Placebo - 0.2% gel vehicle

Updated 9 times since 2017 Last updated: May 18, 2021 Started: Mar 15, 2010 Primary completion: Dec 11, 2010 Completion: Dec 11, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Psoriasis Vulgaris, this trial is completed. The trial is conducted by Eisai Limited and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Sep 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Limited

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany